Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, BioCryst Pharmaceuticals Inc maintains a gross margin of 97.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 64.05%, while the net margin is 60.47%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BCRX competes directly with industry leaders such as STOK and MLYS. With a market capitalization of $2.16B, it holds a significant position in the sector. When comparing efficiency, BCRX's gross margin of 97.66% stands against STOK's 100.00% and MLYS's N/A. Such benchmarking helps identify whether BioCryst Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
